www.horizonscan.nl gebruikt cookies om het gebruik van de website te analyseren en het gebruiksgemak te verbeteren. Lees meer over
cookies
op www.rijkshuisstijl.nl
Sluiten
You are here:
Horizonscan geneesmiddelen
Medicines
Search the site
Search
Chronic immune diseases
All latest versions
5 December 2023
6 June 2023
7 December 2022
7 June 2022
7 December 2021
8 June 2021
8 December 2020
10 June 2020
10 December 2019
12 June 2019
13 December 2018
12 June 2018
9 January 2018
Compact view
Extended view
Grouped by indication
Grouped by status
Grouped by reason of inclusion in Horizonscan Geneesmiddelen
Grouped by submission date
Grouped by expected registration date
Grouped by manufacturer
Grouped by mechanism of action
Grouped by particularity
Grouped by registration phase
Grouped by publication date
Ungrouped
Filters
Sluit
Registration
Show ATMPs only
Show Orphan drugs only
Mechanism of action
Any mechanism of action
Unknown
Alkylating agent
Allergen
Allogeneic modified cell therapy
Amino acid
Anesthetic
Angiogenesis inhibitor
Antiandrogen
Antibiotic
Antibody-drug conjugate
Anticoagulant
Antifungals
Antihistamine
Antioxidant
Antisense oligonucleotide
Autologous modified cell therapy
Bcl-2 inhibitor
BET inhibitor
Calcineurin inhibitor
Cancer vaccine
Cannabinoid
CAR-T therapy
CDK4 / 6 tyrosine kinase inhibitor
CFS1R inhibitor
CGRP-directed antibody
Chelating agent
Coagulant
Combination therapy
Complement inhibitor
Corticosteroid
CTLA-4 antibody
Cytostatic
Disinfectant
Enzyme
Enzyme inhibitor
Enzyme replacement therapy
Gene therapy
GLP-1 receptor agonist
Glucagon analogue
Growth factor
HIV inhibitor
Hormonal therapy
Immunostimulation
Immunosuppression
Insulin preparation
Interferon inhibitor
Interleukin inhibitor
Ion channel blocker
JAK tyrosine kinase inhibitor
LABA / ICS
LABA / LAMA
LABA / LAMA / ICS
LAMA
MEK kinase inhibitor
Neurotoxin
Neurotransmitter
Oncolytic adenovirus
Other
Other, see general comments
PARP inhibitor
PD-1 / PD-L1 inhibitor
Proteasome inhibitor
Protein chaperone
Receptor agonist
Receptor antagonist
Serine / threonine kinase inhibitor
SGLT inhibitor
Small interfering RNA (siRNA)
Sodium channel blocker
Thrombin inhibitor
TNF-alpha inhibitor
Tyrosine kinase inhibitor
Vasodilator
Virus inhibitor
Budgetting framework
Any budgetting framework
Unknown
Extramural (GVS)
Intermural (MSZ)
Particularity
Any particularity
Unknown
New medicine with Priority Medicines (PRIME)
New therapeutical formulation
Reason of inclusion
New medicines
Indication extensions
IND
Biosimilars / generics
BS
G
Download
Bowel diseases
Budesonide
Etrasimod
Filgotinib
IND
Glepaglutide
Guselkumab
Tremfya is geïndiceerd voor de behandeling van volwassen patiënten met matig tot ernstig actieve ziekte van Crohn die onvoldoende hebben gereageerd op, niet meer reageren op of intolerant waren voor conventionele behandeling of een biologische behandeling.
IND
Tremfya is geïndiceerd voor de behandeling van volwassen patiënten met matig tot ernstige colitis ulcerosa die onvoldoende hebben gereageerd op, niet meer reageren op of intolerant waren voor conventionele behandeling of een biologische behandeling.
IND
Mirikizumab
Obefazimod
IND
Risankizumab
IND
Teduglutide
IND
Upadacitinib
G
Ustekinumab
G
Other chronic immune diseases
Arachis hypogaea (pinda) allergenen
IND
Avapritinib
IND
Budesonide
IND
Coacillium topical
FCR 001
Lanadelumab
IND
Leniolisib
Lorecivivint
Marnetegragene autotemcel
Ritlecitinib
Sarilumab
IND
Sebetralstat
Sizavaleucel
Tocilizumab
IND
Voclosporin
Rheumatism
Baricitinib
IND
Bimekizumab
Bimzelx is indicated for the treatment of adults with active non-radiographic axial spondyloarthritis with objective signs of inflammation as indicated by elevated C-reactive protein (CRP) and/or magnetic resonance imaging (MRI) who have responded inadequately or are intolerant to non-steroidal anti-inflammatory drugs (NSAIDs), and for the treatment of adults with active ankylosing spondylitis who have responded inadequately or are intolerant to conventional therapy.
IND
Bimzelx, alone or in combination with methotrexate, is indicated for the treatment of active psoriatic arthritis in adults who have had an inadequate response or who have been intolerant to one or more disease-modifying antirheumatic drugs (DMARDs).
IND
Cyclobenzaprine hydrochloride
Dapansutrile
Sarilumab
IND
Skin diseases
Abrocitinib
Behandeling van matige tot ernstige constutioneel eczeem in adolsecenten
IND
Extension of indication to include treatment of adolescents 12 to < 18 years of age with moderate to severe atopic dermatitis
IND
Baricitinib
IND
Beremagene geperpavec
IND
Bimekizumab
IND
Clascoterone
Concentrate of proteolytic enzymes enriched in bromelain
IND
Dabocemagene autoficel
Delgocitinib
Deucravacitinib
Dupilumab
IND
EB101
Lebrikizumab
Methotrexaat
IND
Nemolizumab
Piclidenoson
Remibrutinib
Roflumilast topicaal
Ruxolitinib phosphate
Opzelura is indicated for the treatment of non-segmental vitiligo with facial involvement in adults and adolescents from 12 years of age.
Matig tot milde atopische dermatitis.
IND
Secukinumab
IND
Sirolimus
Spesolimab
Spevigo is indicated for the treatment of flares in adult patients with generalised pustular psoriasis (GPP) as monotherapy.
Spevigo is indicated for the prevention of flares in adult patients with generalised pustular psoriasis (GPP) as monotherapy.
IND
Unknown
Apremilast
G
Naar boven
National Health Care Institute
Login
Understanding of expected market entry
of innovative medicines
Service
Contact
Downloads
Export
About this site
Copyright
Privacy
Cookies
Toegankelijkheid
Kwetsbaarheid melden
Over de Horizonscan
About the Horizon Scan
Nederlands
English